The Impact of Levosimendan on Mortality in Patients With Severe Heart Failure by Meta-analysis / 中国循环杂志

ABSTRACT

Objective: To investigate the impact of levosimendan on mortality in patients with severe heart failure (HF) by Meta-analysis. Methods: We search the PubMed, EMBASE and Cochrane Central Registry of cardiovascular disease to identify all randomized impact of levosimendan vs other medications. The document retrieval was from the establishment of each database until 2014-07. The literatures were taken based on Jadad scale standard and the qualified control study was used without dose and time restrictions by Rev Man 5.2 soft ware, and a total of 37 articles with 4470 patients were finally enrolled for Meta-analysis. Results: Compared with controlling medications, levosimendan could decrease the mortality in patients with cardiac disease caused severe HF (RR 0.85; 95% CI 0.75-0.97;P=0.02), and cardiac surgery caused severe HF (RR 0.49; 95% CI 0.28-0.85;P=0.01). Compared with dobutamine, levosimendan could reduce the mortality in patients with severe HF (RR 0.84; 95% CI 0.73-0.99;P=0.02) and severe ischemic HF (RR 0.85; 95% CI 0.73-0.99;P=0.04). Conclusion: Levosimendan may reduce the mortality in patients with severe HF caused by cardiac disease, cardiac surgery and ischemic cardiac injury.